Homoharringtonine (HHT) plus cytarabine (Ara-C) for chronic myeloid leukemia in accelerated phase (CML-AP).

被引：0
作者：
Maloisel, F
De Sarrazin, A
Fohrer, C
Rousselot, P
Maisonneuve, H
Lucas, P
Campos, F
Dufour, P
Bergerat, JP
机构：
[1] Hop Civil, Dept Hematol & Oncol, Strasbourg, France
[2] Hop St Louis, Paris, France
[3] CHD, La Roche Sur Yon, France
[4] Polyclin Les Bleuets, Reims, France
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4778
引用
收藏
页码：262B / 262B
页数：1
相关论文
共 50 条
  • [31] Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.
    Radich, Jerald P.
    Martinelli, Giovanni
    Hochhaus, Andreas
    Gottardi, Enrico
    Soverini, Simona
    Branford, Susan
    Mueller, Martin C.
    Beppu, Lan
    Shou, Yaping
    Haque, Ariful
    Woodman, Richard C.
    Kantarjian, Hagop M.
    Hughes, Timothy P.
    Kim, Dong-Wook
    Saglio, Giuseppe
    BLOOD, 2009, 114 (22) : 464 - 465
  • [32] Irinotecan (CPT-11) and cytarabine (Ara-C) in refractory acute myeloid leukemia (AML).
    Minderman, H
    O'Loughlin, KL
    Thomas, KJ
    Pixley, LA
    Wetzler, M
    Slack, JL
    Baer, MR
    LEUKEMIA, 2001, 15 (03) : 509 - 509
  • [33] Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia
    Maiti, Abhishek
    Cortes, Jorge
    Ferrajoli, Alessandra
    Estrov, Zeev
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Ravandi, Farhad
    O'Brien, Susan
    Kantarjian, Hagop
    LEUKEMIA & LYMPHOMA, 2017, 58 (09) : 2240 - 2242
  • [34] SUCCESSFUL SALVAGE TREATMENT WITH CLOFARABINE AND CYTARABINE (ARA-C) IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    Malato, A.
    Santoro, A.
    Felice, R.
    Magrin, S.
    Turri, D.
    Di Bella, R.
    Salemi, D.
    Acquaviva, F.
    Scime, R.
    Fabbiano, F.
    HAEMATOLOGICA, 2013, 98 : 31 - 31
  • [35] Allogeneic bone marrow transplantation (BMT) for adults with chronic myeloid leukemia (CML) in accelerated phase (AP).
    Berkahn, LC
    Fung, HC
    Horsman, DE
    Le, A
    Nantel, SH
    Shepherd, JD
    Toze, CL
    Sutherland, HJ
    Klingemann, HG
    Barnett, MJ
    BLOOD, 1995, 86 (10) : 373 - 373
  • [36] Phase I study of subcutaneous (SC) homoharringtonine (HHT) for patients (pts) with chronic myelogenous leukemia (CML).
    Cortes, J
    O'Brien, S
    Verstovsek, S
    Thomas, D
    Giles, F
    Garcia-Manero, G
    Murgo, A
    Newman, R
    Rios, MB
    Talpaz, M
    Kantarjian, H
    BLOOD, 2003, 102 (11) : 322B - 322B
  • [37] Treatment with α-interferon (IFN) plus intermittent oral Ara-C (YNK-01) in chronic myeloid leukemia (CML) patients resistant to IFN.
    Cervantes, F
    Sureda, A
    Hernández-Boluda, JC
    Brunet, S
    Borrego, D
    Antich, JL
    Martino, R
    Montserrat, E
    BLOOD, 2001, 98 (11) : 255B - 255B
  • [38] Clofarabine combinations in acute myeloid leukemia (AML) salvage: A dose-finding phase I study of clofarabine plus idarubicin and clofarabine/idarubicin plus cytarabine (ara-C)
    Faderl, S
    Ferrajoli, A
    Wierda, W
    Ravandi, F
    Estrov, Z
    Verstovsek, S
    Thomas, DA
    Garcia-Manero, G
    Kwari, M
    Kantarjian, HM
    BLOOD, 2005, 106 (11) : 786A - 786A
  • [39] CLOFARABINE IN COMBINATION WITH CYTARABINE (ARA-C) FOR TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN ADULT PATIENTS
    Malato, A.
    Santoro, A.
    Magrin, S.
    Felice, R.
    Turri, D.
    Di Bella, R.
    Salemi, D.
    Acquaviva, F.
    Scime, R.
    Fabbiano, F.
    HAEMATOLOGICA, 2012, 97 : 502 - 503
  • [40] Survival advantage for patients (pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) treated with imatinib.
    Cortes, J
    Talpaz, M
    O'Brien, S
    Garcia-Manero, G
    Ravandi-Kashami, F
    Giles, F
    Faderl, S
    Wierda, W
    Shan, JQ
    Rios, MB
    Kantaijian, H
    BLOOD, 2004, 104 (11) : 287A - 288A
12345